|1.||Chen, Herbert: 6 articles (06/2010 - 06/2005)|
|2.||Kunnimalaiyaan, Muthusamy: 6 articles (06/2010 - 06/2005)|
|3.||Holen, Kyle: 3 articles (06/2010 - 06/2005)|
|4.||Deming, Dustin: 2 articles (06/2010 - 05/2008)|
|5.||Geiger, Peter: 2 articles (06/2010 - 05/2008)|
|6.||Vaccaro, Abram: 2 articles (05/2008 - 06/2006)|
|7.||Ndiaye, Mary: 1 article (12/2007)|
|8.||Reichardt, Holger M: 1 article (09/2007)|
|9.||Schrama, David: 1 article (09/2007)|
|10.||Ortmann, Sonja: 1 article (09/2007)|
|1.||Carcinoid Tumor (Carcinoid)
06/01/2005 - "In this study, we investigated a novel treatment for carcinoid tumor cell growth based on pharmacologic Raf-1 activation using the compound ZM336372. "
06/01/2005 - "In summary, ZM336372 targets both proliferation and palliative issues associated with carcinoid tumor cells, and therefore, warrants further investigation as a possible therapeutic strategy for patients with carcinoid tumors."
06/01/2005 - "ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells."
12/01/2007 - "We have shown previously that activation of the Raf-1/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling pathway by ZM336372 inhibits carcinoid cells growth. "
06/01/2005 - "Treatment of carcinoid tumor cells with ZM336372 resulted in progressive phosphorylation of Raf-1, mitogen-activated protein kinase 1/2, and extracellular signal-regulated kinase 1/2. Importantly, exposure to ZM336372 resulted in a significant reduction of bioactive hormone levels as well as the transcription factor, human achaete-scute homologue-1 in carcinoid tumor cells. "
12/01/2007 - "In the present study, we further characterize the molecular details of the growth inhibition by the signaling-based compound ZM336372 in neuroendocrine neoplasms (NENs). "
06/01/2006 - "Furthermore, Raf-1 pathway activation by ZM336372 was associated with suppression of NE marker, CgA, by the tumor cells. "
02/01/2006 - "In-vitro activation of Raf-1 in NE tumors either by expression of the ectopic catalytic domain of Raf-1 or by a pharmacologic drug, ZM336372, resulted in growth inhibition. "
09/01/2007 - "Since ERK phosphorylation was also inducible by the Raf-activating pharmacological agent ZM336372, these results provide new perspectives for potential therapeutics for this highly aggressive tumor."
|3.||Neuroendocrine Tumors (Neuroendocrine Tumor)
06/01/2006 - "In pheochromocytoma cells, ZM336372 blocks cellular proliferation and suppresses NE vasoactive peptide production. "
06/01/2006 - "ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells."
06/01/2006 - "Thus, ZM336372 may be used for both therapeutic and palliative treatment for patients with pheochromocytomas."
06/01/2006 - "Treatment of PC-12 cells with increasing dosages of ZM336372 resulted in increased phosphorylated ERK1/2. Importantly, ZM336372 inhibited pheochromocytoma cellular proliferation. "
06/01/2006 - "Pheochromocytoma PC-12 cells were treated with varying concentrations of ZM336372, a pharmacologic Raf-1 activating drug. "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
|2.||Mitogen-Activated Protein Kinase 3
|3.||Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)
|4.||Transcription Factors (Transcription Factor)
|5.||Protein Kinases (Protein Kinase)
|7.||5- iodo- 3- ((3,5- dibromo- 4- hydroxyphenyl)methylene)- 2- indolinone
|8.||glycogen synthase kinase 3 beta
|9.||U 0126 (UO 126)
|2.||Palliative Care (Palliative Medicine)